compound 3797

Compound 3797 is an experimental small molecule antitumor agent designed to disrupt the protein-protein interaction between poly (ADP-ribose) polymerase-1 (PARP1) and the transcription factor E2F1. PARP1 acts as a transcriptional co-activator for E2F1, and their interaction is essential for the hyperactivity of the RB-E2F pathway, which drives uncontrolled cell proliferation in many cancers. By specifically inhibiting this interaction, compound 3797 reduces E2F transcriptional activity in tumor cells, leading to decreased cell growth and migration. The compound was identified through in silico screening of millions of compounds via the Atomwise AIMS Awards Program and is being developed by researchers at the Universidade de Santiago de Compostela and the Kaertor Foundation. Preclinical studies in 2D and 3D models, including patient-derived glioblastoma organoids, have demonstrated its therapeutic potential against glioblastoma.